Tuesday, 17 November 2026European Markets

INVENTIVA Stock Drops By 32% In The Last 21 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - shares of inventiva (cac 40: iva.pa) fell by a staggering 32.49% in 21 sessions from €5.54 to €3.74 at 13:57 est on tuesday, following the last session's downward trend. cac 40 is rising 1.71% to €7,133.01, following the last session's upward trend.

about inventiva

inventiva s.a., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (nash), mucopolysaccharidoses (mps), and other diseases. its lead product candidate is lanifibranor, which has completed phase iib clinical trial to treat nash. the company also develops odiparcil, which has completed phase iia clinical trial for the treatment of mps vi subtype disease. in addition, it has a pipeline of earlier stage programs in oncology and other diseases. the company has strategic collaboration with abbvie for the treatment of autoimmune diseases; and boehringer ingelheim international gmbh for developing new treatments for idiopathic pulmonary fibrosis. inventiva s.a. was founded in 2011 and is based in daix, france.

earnings per share

as for profitability, inventiva has a trailing twelve months eps of €-0.992.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, inventiva's stock is considered to be overbought (>=80).

volatility

inventiva's last week, last month's, and last quarter's current intraday variation average was a negative 1.44%, a negative 2.13%, and a positive 2.16%.

inventiva's highest amplitude of average volatility was 3.54% (last week), 2.61% (last month), and 2.16% (last quarter).

volume

today's last reported volume for inventiva is 10851 which is 70.26% below its average volume of 22241.

more news about inventiva (iva.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 21 Mar 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files